Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Borneo Journal Of Pharmascientech Journal of Pharmaceutical and Sciences.
Andayani , Tri Murti
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Evaluasi Penggunaan Obat Antihipertensi pada Resep Pasien BPJS RSUD Kota Mataram yang Ditebus di Apotek KF 134 Pejanggik dan KF 458 Catur Warga Berdasarkan ATC/DDD dan DU 90% Hamzani, Yogi Mujizat; Andayani , Tri Murti; Dewi, Lucia Vita Inandha
Journal of Pharmaceutical and Sciences JPS Volume 8 Nomor 3 (2025)
Publisher : Fakultas Farmasi Universitas Tjut Nyak Dhien

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36490/journal-jps.com.v8i3.1028

Abstract

Background: Hypertension is a persistent condition of high blood pressure (systolic >140 mmHg or diastolic >90 mmHg). As a chronic disease requiring long-term treatment, the therapy for hypertensive patients needs to be evaluated regularly. Objective: This study aimed to determine the consumption profile of antihypertensive drugs using the ATC/DDD and DU 90% methods and to assess their compliance with the National Formulary (FORNAS). Methods: This research used a cross-sectional design with retrospective data collection. The samples were prescriptions for BPJS hypertension patients from Mataram City Hospital for the period of January-December 2024, redeemed at KF 134 Pejanggik Pharmacy and KF 458 Catur Warga Pharmacy. The data were analyzed using the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) and Drug Utilization 90% (DU 90%) methods. Results: The results showed that the most consumed antihypertensive class was ARBs, specifically candesartan, with a value of 13,082.25 DDD/1000 PPD at KF 134 Pejanggik and 7,215.33 DDD/1000 PPD at KF 458 Catur Warga. The drugs included in the DU 90% segment were candesartan, ramipril, amlodipine, and bisoprolol at both pharmacies, with the addition of valsartan at KF 134 Pejanggik. Compliance with drug use guidelines for FORNAS was 92% at KF 134 Pejanggik Pharmacy and 90% at KF 458 Catur Warga Pharmacy. Conclusion: The use of antihypertensive drugs in both pharmacies is in accordance with FORNAS, with high compliance percentages, indicating rational drug prescribing practices.
Analisis Efektivitas-Biaya Antihipertensi Amlodipin Dibandingkan Candesartan Pada Pasien Stroke Iskemik Rawat Jalan di Rumah Sakit Surakarta Lestari, Rizkia Putri; Andayani , Tri Murti; Rahmawati , Ismi
BORNEO JOURNAL OF PHARMASCIENTECH Vol 10 No 1 (2026): Borneo Journal of Pharmascientech
Publisher : Universitas Borneo Lestari

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.59053/bjp.v10i1.768

Abstract

Hypertension is one of the risk factor for ischemic stroke. Amlodipin and Candesartan are hypertensive therapies in stroke patients. The use of antihypertensive drugs requires long-term treatment, so it is necessary to conduct a cost-effectiveness analysis to determine effective and efficient use of drugs. The purpose of this study is to find out the most cost-saving antihypertensive at Hospital Surakarta. The study was conducted retrospectively on outpatient ischemic stroke patients at the Surakarta Regional General Hospital for the periode 2023-2024. Sample number data used was 114 on ischemic stroke patients according to the inclusion criteria. Effectiveness is seen from the patient's blood pressure reaching the target and the cost is calculated from the provider's perspective, including direct medical costs. CEA is calculated based on the value of ACER and ICER. The results showed the effectiveness of Amlodipin 66,10% and Candesartan 54,55%. The average total cost of Amlodipin is Rp. 556,129 ± 208,187 and Rp. 620,436 ± 232,382 for Candesartan. The value of ACER for amlodipine was Rp. 8,413.44, while candesartan is Rp. 11,377.32. The calculation of the ICER value obtained a negative result Rp. 5,584. The results of the cost-effectiveness analysis showed that amlodipin is a cost-saving antihypertensive for outpatient ischemic stroke patients.
Co-Authors Dewi, Lucia VIta Inandha Hamzani, Yogi Mujizat Lestari, Rizkia Putri Rahmawati , Ismi